COMPARATIVE ANALYSIS OF HEMATOLOGICAL AND BIOCHEMICAL PROFILE CHANGES IN PRE & POST-CHEMOTHERAPY OF BREAST AND OVARIAN CANCER PATIENTS
Main Article Content
Keywords
Ovarian Cancer, Breast cancer, Chemotherapy, Hematological profiles, Biochemical profiles
Abstract
This study focused on 194 female cancer patients who received chemotherapy from July 2018 to December 2022. The median age of the population was 59.5 years. Among these patients, those diagnosed with ovarian cancer had a mean age that was 33% older than 50 years, and breast cancer patients had a mean age that was 37.5% older than 49. The presence of healthcare disparities was underscored by the observation that 70% of individuals diagnosed with ovarian cancer belonged to the most economically disadvantaged social stratum, and delayed onset of menstruation increased the likelihood of developing malignant tumours. Chemotherapy caused significant changes in haematological profiles. The levels of haemoglobin (11.59 ± 1.31 to 11.35 ± 1.42 g/dL), platelets (2.82 ± 1.17 to 2.73 ± 1.10 x10^3/μL), and RBC (4.29 ± 0.52 ± 0.52 x 0.59 x 0.1) μl/6.1 var μ1. all decreased in breast cancer patients compared to ovarian cancer patients. Alkaline phosphate levels were reduced in patients with ovarian cancer, suggesting that chemotherapy caused changes in liver and bone metabolism. On the other hand, breast cancer patients with lower levels of SGPT and total bilirubin had healthier liver function. Both the haematological and biochemical profiles showed positive skewness and kurtosis analysis. This means that the concentrations of bilirubin, SGPT, SGOT, and alkaline phosphate were higher at the upper end. Specifically, bilirubin had a skewness of 1.5 and kurtosis of 3.9, SGPT had a skewness of 1.1 and kurtosis of 2.8, SGOT had a skewness of 1.3 and kurtosis of 3.2, and alkaline phosphatase had a skewness of 1.2 and 3.5 kurtosis. Correlation analysis revealed significant relationships between many parameters, especially between mean corpuscular volume (MCV) and mean corpuscular haemoglobin concentration (MCHC) in ovarian cancer patients, both before (r=0.65, p<0.01) and after (r=0.62, p < 0.01) therapy. reliability study using Cronbach's alpha coefficients showed that MCV had a high level of reliability (α = 0.721) among the haematological parameters. In general, both the biochemical (α = 0.658) and haematological (α = 0.662) profiles showed good reliability. Several factors influence the outcome of chemotherapy, underscoring the need for personalized treatment and vigilant monitoring to improve patient care.
References
1. Gezici, S. and N. Şekeroğlu, Current Perspectives in the Application of Medicinal Plants Against Cancer: Novel Therapeutic Agents. Anti-Cancer Agents in Medicinal Chemistry- Anti-Cancer Agents), 2019. 19(1): p. 101-111.
2. Gaitskell, K., et al., Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK Million Women Study. Cancer Epidemiology, 2022. 76: p. 102074.
3. Anand, U., et al., Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes & Diseases, 2023. 10(4): p. 1367-1401.
4. Zubair, M., S. Wang, and N. Ali, Advanced Approaches to Breast Cancer Classification and Diagnosis. Frontiers in Pharmacology, 2021. 11.
5. Rahman, M.S., S. Suresh, and M.I. Waly, Risk Factors for Cancer: Genetic and Environment, in Bioactive Components, Diet and Medical Treatment in Cancer Prevention, M.I. Waly and M.S. Rahman, Editors. 2018, Springer International Publishing: Cham. p. 1-23.
6. Murphy, N., et al., Lifestyle and dietary environmental factors in colorectal cancer susceptibility. Molecular Aspects of Medicine, 2019. 69: p. 2-9.
7. Pashayan, N. and P.D.P. Pharoah, The challenge of early detection in cancer. Science, 2020. 368(6491): p. 589-590.
8. Testa, U., G. Castelli, and E. Pelosi, Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. Medical Sciences, 2020. 8(1): p. 18.
9. Baugh, E.H., et al., Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death & Differentiation, 2018. 25(1): p. 154-160.
10. Venkitaraman, A.R., How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility? DNA Repair, 2019. 81: p. 102668.
11. Pietragalla, A., et al., Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes. International Journal of Gynecologic Cancer, 2020. 30(11): p. 1803-1810.
12. Aznab, M., et al., The Role of Human Epidermal Growth Factor Receptor (HER2/neu) in the Prognosis of Patients with Gastric Cancer. Asian Pac J Cancer Prev, 2019. 20(7): p. 1989-1994.
13. Pu, H., et al., Regulation of progesterone receptor expression in endometriosis, endometrial cancer, and breast cancer by estrogen, polymorphisms, transcription factors, epigenetic alterations, and ubiquitin-proteasome system. The Journal of Steroid Biochemistry and Molecular Biology, 2023. 227: p. 106199.
14. Hua, H., et al., Mechanisms for estrogen receptor expression in human cancer. Experimental Hematology & Oncology, 2018. 7(1): p. 24.
15. Wan, Z.-B., et al., Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion. Medicine, 2018. 97(44): p. e13055.
16. Lang, A.E. and A.J. Espay, Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. Movement Disorders, 2018. 33(5): p. 660-677.
17. Barani, M., et al., Nanotechnology in ovarian cancer: Diagnosis and treatment. Life Sciences, 2021. 266: p. 118914.
18. Maxwell, S.S., et al., Ovarian cancer in primary care. InnovAiT, 2022. 15(9): p. 525-531.
19. Grimsrud, M.M. and T. Folseraas, Pathogenesis, diagnosis and treatment of premalignant and malignant stages of cholangiocarcinoma in primary sclerosing cholangitis. Liver International, 2019. 39(12): p. 2230-2237.
20. Rickard, B.P., et al., Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response. Cancers, 2021. 13(17): p. 4318.
21. Lisio, M.-A., et al., High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. International Journal of Molecular Sciences, 2019. 20(4): p. 952.
22. Arend, R.C., et al., Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma. Molecular Cancer Research, 2018. 16(5): p. 813-824.
23. Blandino, G. and S. Di Agostino, New therapeutic strategies to treat human cancers expressing mutant p53 proteins. Journal of Experimental & Clinical Cancer Research, 2018. 37(1): p. 30.
24. microRNA as Biomarker in Ovarian Cancer Management: Advantages and Challenges. DNA and Cell Biology, 2020. 39(12): p. 2103-2124.
25. Talaat, A., M.A. Helmy, and S.F. Saadawy, Evaluation of miRNA-21 and CA-125 as a promising diagnostic biomarker in patients with ovarian cancer. Egyptian Journal of Medical Human Genetics, 2022. 23(1): p. 123.
26. Li, R., et al., Damnacanthal isolated from morinda species inhibited ovarian cancer cell proliferation and migration through activating autophagy. Phytomedicine, 2022. 100: p. 154084.
27. Chern, Y.J. and I.T. Tai, Adaptive response of resistant cancer cells to chemotherapy. Cancer Biol Med, 2020. 17(4): p. 842-863.
28. Helcman, M. and K. Šmejkal, Biological activity of Cannabis compounds: a modern approach to the therapy of multiple diseases. Phytochemistry Reviews, 2022. 21(2): p. 429-470.
29. Chan, K.Y., et al., Supportive care and symptom management in patients with advanced hematological malignancies: a literature review. Annals of Palliative Medicine, 2022. 11(10): p. 3273-3291.
30. Prasanna, P.L., K. Renu, and A. Valsala Gopalakrishnan, New molecular and biochemical insights of doxorubicin-induced hepatotoxicity. Life Sciences, 2020. 250: p. 117599.
31. Un, H., et al., A novel effect of Aprepitant: Protection for cisplatin-induced nephrotoxicity and hepatotoxicity. European Journal of Pharmacology, 2020. 880: p. 173168.
32. Yu, Z., et al., Hyperthermic Intraperitoneal Chemotherapy May Damage Renal Function and Cause Serum Electrolyte Disturbance: A Retrospective Observational Study. Surgical Laparoscopy Endoscopy & Percutaneous Techniques, 2023. 33(3): p. 302-309.
33. Aldubayan, M.A., et al., Antineoplastic Activity and Curative Role of Avenanthramides against the Growth of Ehrlich Solid Tumors in Mice. Oxidative Medicine and Cellular Longevity, 2019. 2019: p. 5162687.
34. Rodrigues, D., et al., Drug-induced gene expression profile changes in relation to intestinal toxicity: State-of-the-art and new approaches. Cancer Treatment Reviews, 2019. 77: p. 57-66.
35. Khodabakhshi, A., et al., Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study. Nutrition and Cancer, 2020. 72(4): p. 627-634.
36. Andrade, R.J., et al., Drug-induced liver injury. Nature Reviews Disease Primers, 2019. 5(1): p. 58.
37. Garcia-Cortes, M., et al., Drug induced liver injury: an update. Archives of Toxicology, 2020. 94(10): p. 3381-3407.
38. Dodd, S., et al., Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. The World Journal of Biological Psychiatry, 2018. 19(5): p. 330-348.
39. McGregor, B., et al., Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review. Cancer Treatment Reviews, 2022. 103: p. 102333.
40. Segar, J.L., et al., Fluid management, electrolytes imbalance and renal management in neonates with neonatal encephalopathy treated with hypothermia. Seminars in Fetal and Neonatal Medicine, 2021. 26(4): p. 101261.
41. Brose, M.S., et al., Management of treatment-related toxicities in advanced medullary thyroid cancer. Cancer Treatment Reviews, 2018. 66: p. 64-73.
42. Bruserud, Ø., H.H. Aarstad, and T.H.A. Tvedt, Combined C-Reactive Protein and Novel Inflammatory Parameters as a Predictor in Cancer—What Can We Learn from the Hematological Experience? Cancers, 2020. 12(7): p. 1966.
43. Ali, S., et al., Lipoparticles for Synergistic Chemo-Photodynamic Therapy to Ovarian Carcinoma Cells: In vitro and in vivo Assessments. International Journal of Nanomedicine, 2021. 16(null): p. 951-976.
44. Sidorenkov, G., et al., The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient’s perspective. Journal of Translational Medicine, 2019. 17(1): p. 374.
45. Li, J., et al., A multi-step approach for tongue image classification in patients with diabetes. Computers in Biology and Medicine, 2022. 149: p. 105935.
46. Federici, G. and S. Soddu, Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers. Journal of Experimental & Clinical Cancer Research, 2020. 39(1): p. 46.
47. Hamamoto, R., et al., Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information. Experimental Hematology & Oncology, 2022. 11(1): p. 82.
48. Nguyen, R., et al., A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. Journal for ImmunoTherapy of Cancer, 2019. 7(1): p. 81.
49. Miao, M., et al., A phase II study of apatinib in patients with recurrent epithelial ovarian cancer. Gynecologic Oncology, 2018. 148(2): p. 286-290.
50. Liew, A.C.i., et al., Evaluation of chemotherapy-induced toxicity and health-related quality of life amongst early-stage breast cancer patients receiving Chinese herbal medicine in Malaysia. Supportive Care in Cancer, 2019. 27(12): p. 4515-4524.
51. Dubbelboer, I.R., et al., Liver Cancer Cell Lines Treated with Doxorubicin under Normoxia and Hypoxia: Cell Viability and Oncologic Protein Profile. Cancers, 2019. 11(7): p. 1024.
52. Mohanty, S., et al., Evaluation of Biochemical and Hematological Profile Changes in Cancer Patients Pre- and Postchemotherapy Treatment: A Tertiary Care Teaching Hospital Study. Journal of Datta Meghe Institute of Medical Sciences University, 2021. 16(4): p. 648-652.
53. Chinese Herbal Medicine (Xiaoaiping) Injections for Chemotherapy-Induced Thrombocytopenia: A Randomized, Controlled, Multicenter Clinical Trial. The Journal of Alternative and Complementary Medicine, 2019. 25(6): p. 648-655.
54. Jin, Y., et al., A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors. Frontiers in Pharmacology, 2020. 11.
55. Botlagunta, M., et al., Classification and diagnostic prediction of breast cancer metastasis on clinical data using machine learning algorithms. Scientific Reports, 2023. 13(1): p. 485.
56. Gilmore, N., et al., The longitudinal relationship between immune cell profiles and frailty in patients with breast cancer receiving chemotherapy. Breast Cancer Research, 2021. 23(1): p. 19.
57. Liontos, M., et al., Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy. Journal of Ovarian Research, 2021. 14(1): p. 148.
58. Scott, J.M., et al., Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis. J Clin Oncol, 2018. 36(22): p. 2297-2305.
59. Decanter, C., et al., Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling. Human Reproduction, 2021. 36(10): p. 2743-2752.
60. Chen, W., et al., Organotropism: new insights into molecular mechanisms of breast cancer metastasis. npj Precision Oncology, 2018. 2(1): p. 4.
61. Akhter, T., S. Pervin, and A. Goodman, Quality of life in Ovarian-Cancer patients receiving chemotherapy. Journal of Cancer Therapy, 2020. 11(11): p. 695.
62. Moik, F., et al., Systemic inflammation and activation of haemostasis predict poor prognosis and response to chemotherapy in patients with advanced lung cancer. Cancers, 2020. 12(6): p. 1619.
63. Cristiano, S., et al., Genome-wide cell-free DNA fragmentation in patients with cancer. Nature, 2019. 570(7761): p. 385-389.
64. Siravegna, G., et al., How liquid biopsies can change clinical practice in oncology. Annals of Oncology, 2019. 30(10): p. 1580-1590.
65. Alsaadi, J., Effect of Chemotherapy on hs-C Reactive Protein, Some Blood Picture and Kidney Function in Patients With Neuroblastoma. University of Thi-Qar Journal of Science, 2023. 10(2): p. 81-86.
66. Ogunwobi, O.O., F. Mahmood, and A. Akingboye, Biomarkers in colorectal cancer: current research and future prospects. International journal of molecular sciences, 2020. 21(15): p. 5311.
67. Kouhi Habibi, N., et al., The protective effects of melatonin on blood cell counts of rectal cancer patients following radio-chemotherapy: a randomized controlled trial. Clinical and Translational Oncology, 2019. 21: p. 745-752.
68. Carter, C., Alterations in blood components. Comprehensive toxicology, 2018: p. 249.
69. Brundha, M., V. Pathmashri, and S. Sundari, Quantitative changes of red blood cells in cancer patients under palliative radiotherapy-a retrospective study. Research Journal of Pharmacy and Technology, 2019. 12(2): p. 687-692.
70. Mekonnen, A.T. and T.G. Wondmeneh, Evaluation of liver function tests to identify hepatotoxicity among acute lymphoblastic leukemia patients who are receiving chemotherapy induction. Scientific Reports, 2022. 12(1): p. 13215.
71. Mudd, T.W. and A.K. Guddati, Management of hepatotoxicity of chemotherapy and targeted agents. American journal of cancer research, 2021. 11(7): p. 3461.
72. Kadriyan, H., M.A. Sulaksana, and B.E.S. Nurhidayati, Evaluation Of Renal Function Before And After Chemotherapy In Nasopharyngeal Carcinoma In Lombok. Histopathology. 20(13): p. 60.6.
73. Sales, G.T.M. and R.D. Foresto, Drug-induced nephrotoxicity. Revista da Associação Médica Brasileira, 2020. 66: p. s82-s90.
74. Fernandes, D.P., et al., Hematological and biochemical profile of BALB/c nude and C57BL/6 SCID female mice after ovarian xenograft. Anais da Academia Brasileira de Ciências, 2018. 90(04): p. 3941-3948.
75. Trapani, D., et al., Management of cardiac toxicity induced by chemotherapy. Journal of Clinical Medicine, 2020. 9(9): p. 2885.
76. Nurgali, K., R.T. Jagoe, and R. Abalo, Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae? Frontiers in pharmacology, 2018. 9: p. 362658.
77. Schirrmacher, V., From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment. International journal of oncology, 2019. 54(2): p. 407-419.
78. van den Boogaard, W.M., D.S. Komninos, and W.P. Vermeij, Chemotherapy side-effects: not all DNA damage is equal. Cancers, 2022. 14(3): p. 627.
79. Singh, A., et al., The Effects of Alpha Linolenic Acid (Omega-3 Fatty Acid) on Tobacco Craving Intensity, Withdrawal Symptoms and Biochemical Markers in Tobacco Users. Indian Journal of Clinical Biochemistry, 2024: p. 1-13.
80. Yaqoob, Q.A., et al., Association of Chronic Helicobacter pylori infection with Iron Deficiency Anemia. Annals of the Romanian Society for Cell Biology, 2021. 25(6): p. 1554-1560.
81. Wang, Z., et al., The significance of inflammatory markers in prognosticating the effectiveness and safety of immunotherapy in conjunction with chemotherapy during the primary intervention of advanced non-small cell lung carcinoma. Lung Cancer, 2024: p. 107817.
82. Kotsopoulos, J., et al., BRCA mutation status is not associated with increased hematologic toxicity among patients undergoing platinum-based chemotherapy for ovarian cancer. International Journal of Gynecologic Cancer, 2018. 28(1).
83. Oun, R., Y.E. Moussa, and N.J. Wheate, The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton transactions, 2018. 47(19): p. 6645-6653.
84. Li, X., et al., Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy. Lipids in health and disease, 2018. 17: p. 1-6.
85. Kerian, K., PhD/MMed/MSc at the School of Medical Sciences, Universiti Sains Malaysia.
86. Cui, M.-T., et al., The prognostic roles of red blood cell-associated indicators in patients with resectable gastric cancers. Translational Cancer Research, 2020. 9(4): p. 2300.
87. Xiong, T., A Predictive Model for Pancreatic Cancer Diagnosis. 2021, Massachusetts Institute of Technology.
2. Gaitskell, K., et al., Ovarian cancer survival by stage, histotype, and pre-diagnostic lifestyle factors, in the prospective UK Million Women Study. Cancer Epidemiology, 2022. 76: p. 102074.
3. Anand, U., et al., Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes & Diseases, 2023. 10(4): p. 1367-1401.
4. Zubair, M., S. Wang, and N. Ali, Advanced Approaches to Breast Cancer Classification and Diagnosis. Frontiers in Pharmacology, 2021. 11.
5. Rahman, M.S., S. Suresh, and M.I. Waly, Risk Factors for Cancer: Genetic and Environment, in Bioactive Components, Diet and Medical Treatment in Cancer Prevention, M.I. Waly and M.S. Rahman, Editors. 2018, Springer International Publishing: Cham. p. 1-23.
6. Murphy, N., et al., Lifestyle and dietary environmental factors in colorectal cancer susceptibility. Molecular Aspects of Medicine, 2019. 69: p. 2-9.
7. Pashayan, N. and P.D.P. Pharoah, The challenge of early detection in cancer. Science, 2020. 368(6491): p. 589-590.
8. Testa, U., G. Castelli, and E. Pelosi, Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. Medical Sciences, 2020. 8(1): p. 18.
9. Baugh, E.H., et al., Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death & Differentiation, 2018. 25(1): p. 154-160.
10. Venkitaraman, A.R., How do mutations affecting the breast cancer genes BRCA1 and BRCA2 cause cancer susceptibility? DNA Repair, 2019. 81: p. 102668.
11. Pietragalla, A., et al., Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes. International Journal of Gynecologic Cancer, 2020. 30(11): p. 1803-1810.
12. Aznab, M., et al., The Role of Human Epidermal Growth Factor Receptor (HER2/neu) in the Prognosis of Patients with Gastric Cancer. Asian Pac J Cancer Prev, 2019. 20(7): p. 1989-1994.
13. Pu, H., et al., Regulation of progesterone receptor expression in endometriosis, endometrial cancer, and breast cancer by estrogen, polymorphisms, transcription factors, epigenetic alterations, and ubiquitin-proteasome system. The Journal of Steroid Biochemistry and Molecular Biology, 2023. 227: p. 106199.
14. Hua, H., et al., Mechanisms for estrogen receptor expression in human cancer. Experimental Hematology & Oncology, 2018. 7(1): p. 24.
15. Wan, Z.-B., et al., Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion. Medicine, 2018. 97(44): p. e13055.
16. Lang, A.E. and A.J. Espay, Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. Movement Disorders, 2018. 33(5): p. 660-677.
17. Barani, M., et al., Nanotechnology in ovarian cancer: Diagnosis and treatment. Life Sciences, 2021. 266: p. 118914.
18. Maxwell, S.S., et al., Ovarian cancer in primary care. InnovAiT, 2022. 15(9): p. 525-531.
19. Grimsrud, M.M. and T. Folseraas, Pathogenesis, diagnosis and treatment of premalignant and malignant stages of cholangiocarcinoma in primary sclerosing cholangitis. Liver International, 2019. 39(12): p. 2230-2237.
20. Rickard, B.P., et al., Malignant Ascites in Ovarian Cancer: Cellular, Acellular, and Biophysical Determinants of Molecular Characteristics and Therapy Response. Cancers, 2021. 13(17): p. 4318.
21. Lisio, M.-A., et al., High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints. International Journal of Molecular Sciences, 2019. 20(4): p. 952.
22. Arend, R.C., et al., Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma. Molecular Cancer Research, 2018. 16(5): p. 813-824.
23. Blandino, G. and S. Di Agostino, New therapeutic strategies to treat human cancers expressing mutant p53 proteins. Journal of Experimental & Clinical Cancer Research, 2018. 37(1): p. 30.
24. microRNA as Biomarker in Ovarian Cancer Management: Advantages and Challenges. DNA and Cell Biology, 2020. 39(12): p. 2103-2124.
25. Talaat, A., M.A. Helmy, and S.F. Saadawy, Evaluation of miRNA-21 and CA-125 as a promising diagnostic biomarker in patients with ovarian cancer. Egyptian Journal of Medical Human Genetics, 2022. 23(1): p. 123.
26. Li, R., et al., Damnacanthal isolated from morinda species inhibited ovarian cancer cell proliferation and migration through activating autophagy. Phytomedicine, 2022. 100: p. 154084.
27. Chern, Y.J. and I.T. Tai, Adaptive response of resistant cancer cells to chemotherapy. Cancer Biol Med, 2020. 17(4): p. 842-863.
28. Helcman, M. and K. Šmejkal, Biological activity of Cannabis compounds: a modern approach to the therapy of multiple diseases. Phytochemistry Reviews, 2022. 21(2): p. 429-470.
29. Chan, K.Y., et al., Supportive care and symptom management in patients with advanced hematological malignancies: a literature review. Annals of Palliative Medicine, 2022. 11(10): p. 3273-3291.
30. Prasanna, P.L., K. Renu, and A. Valsala Gopalakrishnan, New molecular and biochemical insights of doxorubicin-induced hepatotoxicity. Life Sciences, 2020. 250: p. 117599.
31. Un, H., et al., A novel effect of Aprepitant: Protection for cisplatin-induced nephrotoxicity and hepatotoxicity. European Journal of Pharmacology, 2020. 880: p. 173168.
32. Yu, Z., et al., Hyperthermic Intraperitoneal Chemotherapy May Damage Renal Function and Cause Serum Electrolyte Disturbance: A Retrospective Observational Study. Surgical Laparoscopy Endoscopy & Percutaneous Techniques, 2023. 33(3): p. 302-309.
33. Aldubayan, M.A., et al., Antineoplastic Activity and Curative Role of Avenanthramides against the Growth of Ehrlich Solid Tumors in Mice. Oxidative Medicine and Cellular Longevity, 2019. 2019: p. 5162687.
34. Rodrigues, D., et al., Drug-induced gene expression profile changes in relation to intestinal toxicity: State-of-the-art and new approaches. Cancer Treatment Reviews, 2019. 77: p. 57-66.
35. Khodabakhshi, A., et al., Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study. Nutrition and Cancer, 2020. 72(4): p. 627-634.
36. Andrade, R.J., et al., Drug-induced liver injury. Nature Reviews Disease Primers, 2019. 5(1): p. 58.
37. Garcia-Cortes, M., et al., Drug induced liver injury: an update. Archives of Toxicology, 2020. 94(10): p. 3381-3407.
38. Dodd, S., et al., Monitoring for antidepressant-associated adverse events in the treatment of patients with major depressive disorder: An international consensus statement. The World Journal of Biological Psychiatry, 2018. 19(5): p. 330-348.
39. McGregor, B., et al., Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review. Cancer Treatment Reviews, 2022. 103: p. 102333.
40. Segar, J.L., et al., Fluid management, electrolytes imbalance and renal management in neonates with neonatal encephalopathy treated with hypothermia. Seminars in Fetal and Neonatal Medicine, 2021. 26(4): p. 101261.
41. Brose, M.S., et al., Management of treatment-related toxicities in advanced medullary thyroid cancer. Cancer Treatment Reviews, 2018. 66: p. 64-73.
42. Bruserud, Ø., H.H. Aarstad, and T.H.A. Tvedt, Combined C-Reactive Protein and Novel Inflammatory Parameters as a Predictor in Cancer—What Can We Learn from the Hematological Experience? Cancers, 2020. 12(7): p. 1966.
43. Ali, S., et al., Lipoparticles for Synergistic Chemo-Photodynamic Therapy to Ovarian Carcinoma Cells: In vitro and in vivo Assessments. International Journal of Nanomedicine, 2021. 16(null): p. 951-976.
44. Sidorenkov, G., et al., The OncoLifeS data-biobank for oncology: a comprehensive repository of clinical data, biological samples, and the patient’s perspective. Journal of Translational Medicine, 2019. 17(1): p. 374.
45. Li, J., et al., A multi-step approach for tongue image classification in patients with diabetes. Computers in Biology and Medicine, 2022. 149: p. 105935.
46. Federici, G. and S. Soddu, Variants of uncertain significance in the era of high-throughput genome sequencing: a lesson from breast and ovary cancers. Journal of Experimental & Clinical Cancer Research, 2020. 39(1): p. 46.
47. Hamamoto, R., et al., Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information. Experimental Hematology & Oncology, 2022. 11(1): p. 82.
48. Nguyen, R., et al., A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia. Journal for ImmunoTherapy of Cancer, 2019. 7(1): p. 81.
49. Miao, M., et al., A phase II study of apatinib in patients with recurrent epithelial ovarian cancer. Gynecologic Oncology, 2018. 148(2): p. 286-290.
50. Liew, A.C.i., et al., Evaluation of chemotherapy-induced toxicity and health-related quality of life amongst early-stage breast cancer patients receiving Chinese herbal medicine in Malaysia. Supportive Care in Cancer, 2019. 27(12): p. 4515-4524.
51. Dubbelboer, I.R., et al., Liver Cancer Cell Lines Treated with Doxorubicin under Normoxia and Hypoxia: Cell Viability and Oncologic Protein Profile. Cancers, 2019. 11(7): p. 1024.
52. Mohanty, S., et al., Evaluation of Biochemical and Hematological Profile Changes in Cancer Patients Pre- and Postchemotherapy Treatment: A Tertiary Care Teaching Hospital Study. Journal of Datta Meghe Institute of Medical Sciences University, 2021. 16(4): p. 648-652.
53. Chinese Herbal Medicine (Xiaoaiping) Injections for Chemotherapy-Induced Thrombocytopenia: A Randomized, Controlled, Multicenter Clinical Trial. The Journal of Alternative and Complementary Medicine, 2019. 25(6): p. 648-655.
54. Jin, Y., et al., A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors. Frontiers in Pharmacology, 2020. 11.
55. Botlagunta, M., et al., Classification and diagnostic prediction of breast cancer metastasis on clinical data using machine learning algorithms. Scientific Reports, 2023. 13(1): p. 485.
56. Gilmore, N., et al., The longitudinal relationship between immune cell profiles and frailty in patients with breast cancer receiving chemotherapy. Breast Cancer Research, 2021. 23(1): p. 19.
57. Liontos, M., et al., Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy. Journal of Ovarian Research, 2021. 14(1): p. 148.
58. Scott, J.M., et al., Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis. J Clin Oncol, 2018. 36(22): p. 2297-2305.
59. Decanter, C., et al., Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling. Human Reproduction, 2021. 36(10): p. 2743-2752.
60. Chen, W., et al., Organotropism: new insights into molecular mechanisms of breast cancer metastasis. npj Precision Oncology, 2018. 2(1): p. 4.
61. Akhter, T., S. Pervin, and A. Goodman, Quality of life in Ovarian-Cancer patients receiving chemotherapy. Journal of Cancer Therapy, 2020. 11(11): p. 695.
62. Moik, F., et al., Systemic inflammation and activation of haemostasis predict poor prognosis and response to chemotherapy in patients with advanced lung cancer. Cancers, 2020. 12(6): p. 1619.
63. Cristiano, S., et al., Genome-wide cell-free DNA fragmentation in patients with cancer. Nature, 2019. 570(7761): p. 385-389.
64. Siravegna, G., et al., How liquid biopsies can change clinical practice in oncology. Annals of Oncology, 2019. 30(10): p. 1580-1590.
65. Alsaadi, J., Effect of Chemotherapy on hs-C Reactive Protein, Some Blood Picture and Kidney Function in Patients With Neuroblastoma. University of Thi-Qar Journal of Science, 2023. 10(2): p. 81-86.
66. Ogunwobi, O.O., F. Mahmood, and A. Akingboye, Biomarkers in colorectal cancer: current research and future prospects. International journal of molecular sciences, 2020. 21(15): p. 5311.
67. Kouhi Habibi, N., et al., The protective effects of melatonin on blood cell counts of rectal cancer patients following radio-chemotherapy: a randomized controlled trial. Clinical and Translational Oncology, 2019. 21: p. 745-752.
68. Carter, C., Alterations in blood components. Comprehensive toxicology, 2018: p. 249.
69. Brundha, M., V. Pathmashri, and S. Sundari, Quantitative changes of red blood cells in cancer patients under palliative radiotherapy-a retrospective study. Research Journal of Pharmacy and Technology, 2019. 12(2): p. 687-692.
70. Mekonnen, A.T. and T.G. Wondmeneh, Evaluation of liver function tests to identify hepatotoxicity among acute lymphoblastic leukemia patients who are receiving chemotherapy induction. Scientific Reports, 2022. 12(1): p. 13215.
71. Mudd, T.W. and A.K. Guddati, Management of hepatotoxicity of chemotherapy and targeted agents. American journal of cancer research, 2021. 11(7): p. 3461.
72. Kadriyan, H., M.A. Sulaksana, and B.E.S. Nurhidayati, Evaluation Of Renal Function Before And After Chemotherapy In Nasopharyngeal Carcinoma In Lombok. Histopathology. 20(13): p. 60.6.
73. Sales, G.T.M. and R.D. Foresto, Drug-induced nephrotoxicity. Revista da Associação Médica Brasileira, 2020. 66: p. s82-s90.
74. Fernandes, D.P., et al., Hematological and biochemical profile of BALB/c nude and C57BL/6 SCID female mice after ovarian xenograft. Anais da Academia Brasileira de Ciências, 2018. 90(04): p. 3941-3948.
75. Trapani, D., et al., Management of cardiac toxicity induced by chemotherapy. Journal of Clinical Medicine, 2020. 9(9): p. 2885.
76. Nurgali, K., R.T. Jagoe, and R. Abalo, Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae? Frontiers in pharmacology, 2018. 9: p. 362658.
77. Schirrmacher, V., From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment. International journal of oncology, 2019. 54(2): p. 407-419.
78. van den Boogaard, W.M., D.S. Komninos, and W.P. Vermeij, Chemotherapy side-effects: not all DNA damage is equal. Cancers, 2022. 14(3): p. 627.
79. Singh, A., et al., The Effects of Alpha Linolenic Acid (Omega-3 Fatty Acid) on Tobacco Craving Intensity, Withdrawal Symptoms and Biochemical Markers in Tobacco Users. Indian Journal of Clinical Biochemistry, 2024: p. 1-13.
80. Yaqoob, Q.A., et al., Association of Chronic Helicobacter pylori infection with Iron Deficiency Anemia. Annals of the Romanian Society for Cell Biology, 2021. 25(6): p. 1554-1560.
81. Wang, Z., et al., The significance of inflammatory markers in prognosticating the effectiveness and safety of immunotherapy in conjunction with chemotherapy during the primary intervention of advanced non-small cell lung carcinoma. Lung Cancer, 2024: p. 107817.
82. Kotsopoulos, J., et al., BRCA mutation status is not associated with increased hematologic toxicity among patients undergoing platinum-based chemotherapy for ovarian cancer. International Journal of Gynecologic Cancer, 2018. 28(1).
83. Oun, R., Y.E. Moussa, and N.J. Wheate, The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton transactions, 2018. 47(19): p. 6645-6653.
84. Li, X., et al., Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy. Lipids in health and disease, 2018. 17: p. 1-6.
85. Kerian, K., PhD/MMed/MSc at the School of Medical Sciences, Universiti Sains Malaysia.
86. Cui, M.-T., et al., The prognostic roles of red blood cell-associated indicators in patients with resectable gastric cancers. Translational Cancer Research, 2020. 9(4): p. 2300.
87. Xiong, T., A Predictive Model for Pancreatic Cancer Diagnosis. 2021, Massachusetts Institute of Technology.
Article Sidebar
Published
Jul 30, 2024
Article Details
How to Cite
Umair Yousaf, Rooma Adalat, Tafseer Fatima, Kashif Islam, Farwa Rasheed, Javeria Taj, Aneeza Arif, Khansa Naseem, & Imran Zafar. (2024). COMPARATIVE ANALYSIS OF HEMATOLOGICAL AND BIOCHEMICAL PROFILE CHANGES IN PRE & POST-CHEMOTHERAPY OF BREAST AND OVARIAN CANCER PATIENTS. Journal of Population Therapeutics and Clinical Pharmacology, 31(7), 1284-1305. https://doi.org/10.53555/jptcp.v31i7.7254
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Author Biographies
Umair Yousaf
Department of Zoology, University of Sialkot, Sialkot, Pakistan
Rooma Adalat
Department of Zoology, University of Sialkot, Sialkot, Pakistan
Tafseer Fatima
Medical of Physics, Gujranwala Institute of Nuclear Medicine
Kashif Islam
Department of Zoology, University of Sialkot, Sialkot, Pakistan
Farwa Rasheed
Department of Zoology, University of Sialkot, Sialkot, Pakistan
Javeria Taj
Department of Zoology, University of Sialkot, Sialkot, Pakistan
Aneeza Arif
Department of Zoology, University of Sialkot, Sialkot, Pakistan
Khansa Naseem
Department of Chemistry, University of Lahore, Punjab Pakistan.
Imran Zafar
Department of Bioinformatics and Computational Biology Virtual University Pakistan
How to Cite
Umair Yousaf, Rooma Adalat, Tafseer Fatima, Kashif Islam, Farwa Rasheed, Javeria Taj, Aneeza Arif, Khansa Naseem, & Imran Zafar. (2024). COMPARATIVE ANALYSIS OF HEMATOLOGICAL AND BIOCHEMICAL PROFILE CHANGES IN PRE & POST-CHEMOTHERAPY OF BREAST AND OVARIAN CANCER PATIENTS. Journal of Population Therapeutics and Clinical Pharmacology, 31(7), 1284-1305. https://doi.org/10.53555/jptcp.v31i7.7254